PCIA
JAZZ icon

Prime Capital Investment Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Prime Capital Investment Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,014
Closed -$512K – 1084
2025
Q4 		$512K Buy
3,014
+455
+18% +$69.8K 0.01% 649
2025
Q3 		$337K Sell
2,559
-21
-0.8% -$2.52K ﹤0.01% 767
2025
Q2 		$274K Sell
2,580
-72
-3% -$7.82K ﹤0.01% 794
2025
Q1 		$329K Buy
2,652
+27
+1% +$3.52K ﹤0.01% 805
2024
Q4 		$323K Buy
2,625
+6
+0.2% +$707 ﹤0.01% 705
2024
Q3 		$292K Sell
2,619
-2
-0.1% -$219 ﹤0.01% 746
2024
Q2 		$280K Buy
2,621
+36
+1% +$3.96K ﹤0.01% 744
2024
Q1 		$311K Sell
2,585
-61
-2% -$7.47K ﹤0.01% 766
2023
Q4 		$325K Buy
2,646
+108
+4% +$13.5K ﹤0.01% 713
2023
Q3 		$329K Buy
2,538
+16
+0.6% +$2.13K 0.01% 561
2023
Q2 		$313K Buy
+2,522
New +$339K 0.01% 594
2019
Q2 		– Sell
-186
Closed -$27K – 374
2019
Q1 		$27K Buy
+186
New +$24.3K 0.01% 222

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prime Capital Investment Advisors's JAZZ Position: Q1 2026 in Review

Prime Capital Investment Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 3,014 shares — an estimated $512K sold.

Prime Capital Investment Advisors first reported a position in JAZZ in Q1 2019 and held it in 12 quarters. The position peaked at $512K in Q4 2025. 573 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Prime Capital Investment Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 3,014 Jazz Pharmaceuticals shares in Q1 2026, an estimated $512K.
  • Prime Capital Investment Advisors first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 12 quarters.
  • Prime Capital Investment Advisors's Jazz Pharmaceuticals position peaked at $512K in Q4 2025.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.